explore -WSS

explore

author：knowledge 2025-10-01 05:40:15 - browse：54766

Seng Cheng has been working in gene therapy for nearly as long as gene therapy has been a field. As a young scientist in the early 1990s, he was part of one of three teams racing to develop a gene therapy for cystic fibrosis, a high-profile effort that resulted in national headlines, prestigious publications, and zero patients cured.

So he’s seen the field’s highs and lows. Lately, there have been a lot of both, including at Pfizer, the company Cheng called home until this summer. The pharma brought three potentially powerful gene therapies for muscular dystrophy and hemophilia into late-stage trials but, in January, chose to abandon a large portfolio of early stage candidates that relied on the same technology: adeno-associated viruses, or AAVs, a group of small bugs that scientists spent two decades taming into a gene shipping system.

The move seemed emblematic. Across the industry, AAV companies have been struggling, either shelving programs or stopping work altogether, while investors shuttled money toward new technologies such as CRISPR and its various permutations. Longtime researchers feared promising drugs, particularly for ultra-rare diseases, might get lost in the shuffle.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

WSS

J&J to buy cancer drug developer Ambrx Biopharma

New weight loss drugs work. But how can they best be used?

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

How a scoliosis diagnosis changed the life of one young dancer

3 medical device trends to watch in 2024

CVS Caremark has created a new ploy: the drug ‘rebate credit’

leisure time

explore

leisure time

Drug repurposing or repositioning? The language matters

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

The FDA must approve intranasal treatments for anaphylaxis

23andMe had bad news about my health. I wish a person had delivered it

Orchard's therapy for neuron disease in children wins FDA approval

At least 13 dead in Texas as scorching temps continue

U.K. researchers warn about biases in medical devices, algorithms

Supreme Court strikes down use of affirmative action

J&J to buy cancer drug developer Ambrx Biopharma

explore

Asbestos, a deadly carcinogen, banned by EPA

AdventHealth escalates lawsuit against insurance vendor Multiplan

The biotech scorecard for Q1: 17 stock

Neuroscience’s long legacy of racism

How a scoliosis diagnosis changed the life of one young dancer

GSK Flovent asthma inhalers replaced by authorized generics

focus

leisure time

Wikipedia

hotspot